ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Wednesday, November 15, 2023

9:00AM-10:30AM: Abstract Number: 2580

High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

9:00AM-10:30AM: Abstract Number: 2571

Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2578

Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

9:00AM-10:30AM: Abstract Number: 2573

Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2576

Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

9:00AM-10:30AM: Abstract Number: 2564

The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2565

The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021

Abstracts: Epidemiology & Public Health III

9:00AM-10:30AM: Abstract Number: 2570

Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III

9:00AM-10:30AM: Abstract Number: 2579

Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2598

6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

11:00AM-12:30PM: Abstract Number: 2586

A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2583

A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2595

A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

11:00AM-12:30PM: Abstract Number: 2590

Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE)

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes IV: Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2600

Clonal Hematopoiesis Is Associated with Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].